10 terminated. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 10 |
| Phase 1 | 1 | Terminated 1 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Functional Outcomes After Bilateral, 3D Ultrasound-guided Focal Thermal Ablation of the Prostate Transition Zone, in Patients With Benign Prostatic Hyperplasia-related Obstruction Targeted Microwave Ablation - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 8 | 2024-04-24 | 2026-10-01 |
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | OPKO Health, Inc. | 114 | 2018-02-21 | 2021-09-16 |
| Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Embosphere microspheres - Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms | Phase 1 / Phase 2 | Terminated | Rhode Island Hospital | 9 | 2015-12-01 | 2021-07-08 |
| Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Embosphere Microspheres - Prostatic Hyperplasia | Phase 2 | Terminated | South Florida Medical Imaging, PA | 2 | 2015-09-24 | 2018-11-06 |
| TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) Docetaxel, TroVax - Hormone Refractory Prostate Cancer | Phase 2 | Terminated | Oxford BioMedica | 25 | 2010-08-01 | 2020-10-19 |
| A Study in Men With Benign Prostatic Hyperplasia LY500307, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Eli Lilly and Company | 414 | 2010-04-01 | 2019-04-08 |
| Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH) ozarelix, Placebo - Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 28 | 2008-12-04 | 2021-11-22 |
| A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) etonogestrel, Placebo - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Terminated | Organon and Co | 16 | 2008-03-01 | 2026-04-08 |
| Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia Lonidamine - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Threshold Pharmaceuticals | 240 | 2005-06-01 | 2009-04-29 |
| Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS) Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system - Prostatic Hyperplasia | Phase 2 | Terminated | QLT Inc. | 180 | 2005-05-01 | 2006-10-03 |
Lower Urinary Tract Symptoms (3) · Prostatic Neoplasms (1)
Genital Diseases (10) · Genital Diseases, Male (10) · Male Urogenital Diseases (10) · Prostatic Diseases (10) · Urogenital Diseases (10) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Urological Manifestations (3) · Genital Neoplasms, Male (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Neoplasms (1)
Docetaxel (1) · Injections (1) · TroVax (1) · erteberel (1) · etonogestrel (1) · lemuteporfin (1) · lonidamine (1) · ozarelix (1)
Assistance Publique - Hôpitaux de Paris (1) · Eli Lilly and Company (1) · OPKO Health, Inc. (1) · Organon and Co (1) · Oxford BioMedica (1) · QLT Inc. (1) · Rhode Island Hospital (1) · South Florida Medical Imaging, PA (1) · Spectrum Pharmaceuticals, Inc (1) · Threshold Pharmaceuticals (1)
United States (8) · Canada (2) · France (2) · Argentina (1) · Australia (1) · Germany (1) · Greece (1) · Italy (1) · Russia (1)
Anna C. Ferrari, MD (1) · Graeme Boniface, PhD (1) · Michael Rush, MD (1) · Militza Vera De Alba, MD (1)